Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.

Li R, Baskfield A, Lin Y, Beers J, Zou J, Liu C, Jaffré F, Roberts AE, Ottinger EA, Kontaridis MI, Zheng W.

Stem Cell Res. 2019 Jan;34:101374. doi: 10.1016/j.scr.2018.101374. Epub 2018 Dec 26.

2.

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.

Wiederhold NP, Xu X, Wang A, Najvar LK, Garvey EP, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Brand SR, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01315-18. doi: 10.1128/AAC.01315-18. Print 2018 Nov.

3.

In vitro and in vivo translational models for rare liver diseases.

Haugabook SJ, Ferrer M, Ottinger EA.

Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):1003-1018. doi: 10.1016/j.bbadis.2018.07.029. Epub 2018 Aug 1. Review.

PMID:
30075192
4.

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.

Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01071-18. doi: 10.1128/AAC.01071-18. Print 2018 Sep.

5.

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses.

Sima N, Li R, Huang W, Xu M, Beers J, Zou J, Titus S, Ottinger EA, Marugan JJ, Xie X, Zheng W.

Orphanet J Rare Dis. 2018 Apr 10;13(1):54. doi: 10.1186/s13023-018-0798-2.

6.

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.

Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, Berry-Kravis E, Davidson CD, Bianconi S, Keener LA, Rao R, Soldatos A, Sidhu R, Walters KA, Xu X, Thurm A, Solomon B, Pavan WJ, Machielse BN, Kao M, Silber SA, McKew JC, Brewer CC, Vite CH, Walkley SU, Austin CP, Porter FD.

Lancet. 2017 Oct 14;390(10104):1758-1768. doi: 10.1016/S0140-6736(17)31465-4. Epub 2017 Aug 10.

7.

Fostering collaborative research for rare genetic disease: the example of niemann-pick type C disease.

Walkley SU, Davidson CD, Jacoby J, Marella PD, Ottinger EA, Austin CP, Porter FD, Vite CH, Ory DS.

Orphanet J Rare Dis. 2016 Dec 1;11(1):161.

8.

Disease models for the development of therapies for lysosomal storage diseases.

Xu M, Motabar O, Ferrer M, Marugan JJ, Zheng W, Ottinger EA.

Ann N Y Acad Sci. 2016 May;1371(1):15-29. doi: 10.1111/nyas.13052. Epub 2016 May 4. Review.

9.

Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M, Brewster M, Scott I, Xu X, Cradock J, Terse P, Dehdashti SJ, Marugan J, Zheng W, Portilla L, Hubbs A, Pavan WJ, Heiss J, Vite CH, Walkley SU, Ory DS, Silber SA, Porter FD, Austin CP, McKew JC.

Curr Top Med Chem. 2014;14(3):330-9. Review.

10.

Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.

Caulfield MJ, Dudkin VY, Ottinger EA, Getty KL, Zuck PD, Kaufhold RM, Hepler RW, McGaughey GB, Citron M, Hrin RC, Wang YJ, Miller MD, Joyce JG.

J Biol Chem. 2010 Dec 24;285(52):40604-11. doi: 10.1074/jbc.M110.172197. Epub 2010 Oct 13.

11.

Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides.

Maiolo JR, Ferrer M, Ottinger EA.

Biochim Biophys Acta. 2005 Jun 30;1712(2):161-72.

12.

Specific redistribution of cell-penetrating peptides from endosomes to the cytoplasm and nucleus upon laser illumination.

Maiolo JR 3rd, Ottinger EA, Ferrer M.

J Am Chem Soc. 2004 Dec 1;126(47):15376-7.

PMID:
15563153
13.

Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1.

Dhe-Paganon S, Ottinger EA, Nolte RT, Eck MJ, Shoelson SE.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8378-83.

14.

Modular folding and evidence for phosphorylation-induced stabilization of an hsp90-dependent kinase.

Hartson SD, Ottinger EA, Huang W, Barany G, Burn P, Matts RL.

J Biol Chem. 1998 Apr 3;273(14):8475-82.

15.

Tandem SH2 domains confer high specificity in tyrosine kinase signaling.

Ottinger EA, Botfield MC, Shoelson SE.

J Biol Chem. 1998 Jan 9;273(2):729-35.

16.

Human GRB-IRbeta/GRB10. Splice variants of an insulin and growth factor receptor-binding protein with PH and SH2 domains.

Frantz JD, Giorgetti-Peraldi S, Ottinger EA, Shoelson SE.

J Biol Chem. 1997 Jan 31;272(5):2659-67.

18.

In vitro association of the phosphatidylinositol 3-kinase regulatory subunit (p85) with the human insulin receptor.

Ottinger EA, Hui TY, Man Z, Barany G, Bernlohr DA.

Int J Pept Protein Res. 1995 Nov;46(5):346-53.

PMID:
8567177
19.

Synthesis of phosphotyrosine-containing peptides and their use as substrates for protein tyrosine phosphatases.

Ottinger EA, Shekels LL, Bernlohr DA, Barany G.

Biochemistry. 1993 Apr 27;32(16):4354-61.

PMID:
7682846

Supplemental Content

Loading ...
Support Center